Regeneron Pharmaceuticals Inc (REGN)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	10,961,800	10,703,800	10,401,900	10,100,800	10,203,900	7,697,000	7,334,100	7,195,500	7,154,000	11,286,100	11,899,500	14,120,400	13,727,400	12,055,800	11,041,700	8,066,200	7,412,500	7,159,100	6,835,400	6,746,100
Revenue (ttm)	US$ in thousands	14,185,900	13,812,700	13,436,900	13,029,000	13,044,200	13,025,200	12,601,200	12,306,100	12,113,500	13,654,100	14,171,800	16,451,800	16,014,400	13,499,700	12,328,800	9,147,000	8,455,000	8,201,600	7,974,500	7,957,900
Gross profit margin		77.27%	77.49%	77.41%	77.53%	78.23%	59.09%	58.20%	58.47%	59.06%	82.66%	83.97%	85.83%	85.72%	89.30%	89.56%	88.18%	87.67%	87.29%	85.72%	84.77%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $10,961,800K ÷ $14,185,900K
= 77.27%

The gross profit margin of Regeneron Pharmaceuticals Inc has fluctuated over the past years based on the provided data. It increased steadily from March 31, 2020, at 84.77% to reach a peak of 89.56% on June 30, 2021. However, there was a slight decline in the following period, with the gross profit margin dropping to 85.72% by December 31, 2021.

Subsequently, there were further fluctuations in the gross profit margin, with a decrease observed by the end of December 31, 2022, to 59.06%. This significant drop may raise concerns about the company's cost management and pricing strategies during that period. The gross profit margin continued to exhibit fluctuations in the following quarters, but it recovered slightly to 78.27% by December 31, 2024.

Overall, Regeneron Pharmaceuticals Inc's gross profit margin has shown variability, signaling potential changes in the company's cost structure, pricing strategies, or sales mix. Further analysis would be required to assess the underlying reasons for these fluctuations and their impact on the company's financial performance.